The Pharma Data

JANUARY 7, 2021

The pharmaceutical product landscape is rapidly and fundamentally changing with profound impact on research and development strategy and technology needs. The number of biopharmaceutical products show a considerable growth accounting for nearly a quarter of the new molecular entities approved in 2017.

Bioavailability 52

Bioavailability Production Manufacturing Drugs 52

Cloudbyz

MARCH 5, 2024

The difference between biologics vs small molecules in pharma drug development In pharmaceutical drug development, biologics and small molecules represent two distinct categories of medicinal products, each with their own unique characteristics, development processes, and mechanisms of action.

Development 97

Development Drugs Manufacturing Immune Response 97

Roots Analysis

MAY 21, 2024

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Roots Analysis

MARCH 2, 2022

One of the key objectives behind the aforementioned developments is to overcome issues related to high costs associated with the design and production of such pharmacological interventions. Clinical Research Landscape of Oral Peptide and Protein-based Therapeutics. Oral Proteins and Peptides Market (4th Edition). Web: [link].

Protein 52

Protein Drugs Drug Delivery Drug Delivery Systems 52

Delveinsight

FEBRUARY 16, 2021

Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry. Takeda wins big in cytomegalovirus infection market.

Marketing 52

Marketing Protein Bioavailability Drugs 52

Pharmaceutical Technology

JUNE 26, 2022

Placing traditionally siloed drug substance and drug product development activities within a single organization that also has commercial manufacturing capabilities accelerates clinical development and builds in quality and robustness of supply. Streamlined processes to reduce time to market for drugs. Polymorphic form issues.

Manufacturing 130

Manufacturing Drugs Production Development 130

Roots Analysis

OCTOBER 2, 2023

Additionally, it increases the bioavailability and solubility of the attached molecule. In fact, in the last twenty years, the United States Food and Drug Administration (USFDA) and the European Medicines Agency (EMA) have authorized the market approval of around 80 nanomedicines.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Marketing 40

Roots Analysis

MARCH 13, 2022

In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide. Furthermore, excipients play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs).

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Roots Analysis

SEPTEMBER 1, 2023

By charting new waters and creating uncontested market spaces, companies can differentiate themselves and unlock unprecedented growth opportunities. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

The Pharma Data

DECEMBER 9, 2020

Spun out of CEO and co-founder Evan Feinberg’s breakthrough artificial Intelligence (AI) research at Stanford University’s Pande Lab , Genesis Therapeutics is applying the resulting influential PotentialNet neural network algorithm to unify AI and biotech against a range of diseases with unmet needs. Genesis Therapeutics.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

MARCH 11, 2021

Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, to be held virtually April 10-15, 2021. Session Category: Clinical Research (Excluding Trials). Abstract Number: 442.

Research 52

Research Clinical Trials Clinical Trials Trials 52

XTalks

MAY 23, 2024

Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays. These include broad-spectrum sunscreens, protective clothing and innovative skincare products developed using antioxidants and other protective agents. How is Medicus Pharma innovating in this space?

Life Science 72

Life Science Dermatology Drug Delivery Systems Medicine 72

The Pharma Data

JANUARY 27, 2021

As a bioscience accelerator at the leading-edge of the life science industry, XPhyto targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. . VANCOUVER, BC / ACCESSWIRE / January 28, 2021 / XPhyto Therapeutics Corp.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

XTalks

FEBRUARY 3, 2023

Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics and a wholly owned subsidiary of the Menarini Group, will market Orserdu in the US. ER+, HER2- Breast Cancer ER+, HER2- cancers account for about 75 percent of breast cancers.

Clinical Trials 83

Clinical Trials Clinical Trials FDA Approval Trials 83

Delveinsight

JULY 30, 2020

The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 In patients with CALD, Adrenoleukodystrophy market offers two therapies, namely Lorenzo’s oil and haematopoietic stem cell transplantation (HSCT) , using either umbilical cord stem cells or bone marrow stem cells.

Hormones 52

Hormones Marketing Gene Trials 52

Delveinsight

JANUARY 7, 2021

Omega Funds led the series B round with assists from fellow new investor Fidelity Management & Research and existing backers Atlas Venture, OrbiMed, and Bristol Myers Squibb, which became involved through its Celgene acquisition. The startup recently raised USD 87 million to propel itself in a competitive market.

RNA 52

RNA Clinical Trials Clinical Trials Trials 52

The Pharma Data

NOVEMBER 19, 2020

These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies. The Company has created a covid19@soseiheptares.com contact address for companies and researchers who would like to discuss possible collaborations.

Development 40

Development Bioavailability Production Drugs 40

Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Significance: Pirfenidone might have a differential effect on FVC change in patients with uILD depending on baseline concomitant MMF treatment status-further research is required. Ofev (Nintedanib) Facts.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

The Pharma Data

NOVEMBER 17, 2020

LYT-100 is PureTech’s wholly-owned product candidate that is being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow. LYT-100 is PureTech’s most advanced wholly-owned product candidate. This press release features multimedia. Photo: Business Wire). About LYT-100.

Production 52

Production Trials Bioavailability Drugs 52

The Pharma Data

APRIL 11, 2023

Notably, these presentations include new data from dose proportionality and bioequivalence studies, which supported the FDA approval of once-daily AUSTEDO XR extended-release tablets – demonstrating AUSTEDO XR is therapeutically equivalent to the currently marketed twice-daily AUSTEDO. Source link: [link]

Bioequivalency 40

Bioequivalency FDA Approval Medicine Bioavailability 40

Camargo

SEPTEMBER 30, 2021

Drug product formulation should be as simple as possible, but carefully executed to account for the characteristics of the intended administration route and dosing regimen and to facilitate successful manufacturing, storage, shipping, and compliance in the clinic and eventually on the market. Camargo Research Group.

Development 201

Development Research Manufacturing In-Vivo 201

XTalks

AUGUST 30, 2022

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. Global sales of over-the-counter and prescription products related to central nervous system (CNS) disease added up to $86 billion in 2019.

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

DECEMBER 1, 2020

The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. Axsome’s core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14.

Trials 52

Trials Clinical Trials Clinical Trials Production 52

FDA Law Blog

JULY 9, 2024

Livornese — The Food and Drug Omnibus Reform Act (“FDORA”), enacted in December 2022, added a requirement that sponsors submit Diversity Action Plans (“DAPs”) for certain clinical studies involving drugs, biological products, or devices (codified at 21 U.S.C. § 355(z)(3) and 21 U.S.C. 360j(g)(9)(A)). population demographics.

Clinical Trials 59

Clinical Trials Clinical Trials Development Drugs 59

Pharmaceutical Technology

DECEMBER 19, 2022

This question forms the basis of a new scientific research paper, Nanomilling and size characterization of highly concentrated API suspensions from Fribourg University, Switzerland, which details experiments using nanomilling techniques to reduce micron sized particles further down to nanometric size, thus useful for the pharmaceutical industry.

Production 130

Production Bioavailability Biohazard Biohazard 130

The Pharma Data

MAY 16, 2021

Product Name: Warrior's Secret. If within the first 60 days of receipt you are not satisfied with Wake Up Lean , you can request a refund by sending an email to the address given inside the product and we will immediately refund your entire purchase price, with no questions asked. Sex-Crazed Warlord’s Battlefield Ritual.

Production 52

Production Containment Research Doctors 52